Advisory Committee for Pharmaceutical Science and Clinical Pharmacology; Notice of Meeting, 26249-26250 [E9-12627]
Download as PDF
Federal Register / Vol. 74, No. 103 / Monday, June 1, 2009 / Notices
listing information, unless a waiver is
granted.
ADDRESSES: Submit written requests for
single copies of this guidance to the
Office of Critical Path Programs (HF–
18), Office of the Commissioner, Food
and Drug Administration, 5600 Fishers
Lane, Rockville, MD 20857. Send one
self-addressed adhesive label to assist
that office in processing your requests.
The guidance may also be obtained by
mail by calling the Office of Critical
Path Programs at 301–827–1512. Submit
written comments on the guidance to
the Division of Dockets Management
(HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. Submit
electronic comments to https://
www.regulations.gov. See the
SUPPLEMENTARY INFORMATION section for
electronic access to the guidance
document.
FOR FURTHER INFORMATION CONTACT:
Lonnie Smith, Office of Critical Path
Programs (HF–18), Office of the
Commissioner, Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–594–0011.
SUPPLEMENTARY INFORMATION:
I. Background
Requirements for drug establishment
registration and drug listing are set forth
in section 510 of the Federal Food,
Drug, and Cosmetic Act (the act) (21
U.S.C. 360) and section 351 of the
Public Health Service Act (the PHS Act)
(42 U.S.C. 262) and 21 CFR part 207.
Fundamental to FDA’s mission to
protect the public health is the
collection of this information, which is
used for important activities such as
postmarket surveillance for serious
adverse drug reactions, inspection of
drug manufacturing and processing
facilities, and monitoring of drug
products imported into the United
States. Comprehensive, accurate, and
up-to-date information is critical to
conducting these activities with
efficiency and effectiveness.
Changes in the act, resulting from the
Food and Drug Administration
Amendments Act of 2007 (FDAAA)
(Public Law 110–85), require that drug
establishment registration and drug
listing information be submitted
electronically, unless a waiver is
granted. Before FDAAA was enacted,
section 510(p) of the act expressly
provided that drug establishment
registration information must be
submitted electronically, based on a
finding that electronic receipt was
feasible, and section 510(j) of the act
stipulated that drug listing information
must be submitted in the form and
VerDate Nov<24>2008
15:29 May 29, 2009
Jkt 217001
manner prescribed by FDA. Section 224
of FDAAA, which amends section
510(p) of the act, now expressly requires
drug listing to be submitted by
electronic means in addition to
requiring electronic drug establishment
registration.
Drug establishment registration and
drug listing information have, until
now, been submitted using a paperbased format, i.e., Form FDA 2656
(Registration of Drug Establishment/
Labeler Code Assignment), Form FDA
2657 (Drug Product Listing), and Form
FDA 2658 (Registered Establishments’
Report of Private Label Distributors).
Moving from a paper-based format to an
electronic system will improve the
timeliness and accuracy of the
submissions.
This guidance is designed to assist
manufacturers, repackers, and relabelers
with electronic submissions of drug
establishment registrations and drug
listing information. The guidance and
accompanying technical documents
explain (among other things):
• The statutory requirement to submit
electronically drug establishment
registration and drug listing
information;
• How to create a Structured Product
Labeling (SPL) file for submitting drug
establishment registration and drug
listing information to FDA through the
Electronic Submissions Gateway (ESG)
using defined code sets and codes, i.e.,
a language recognized by the computer
system; and
• That FDA intends to no longer
accept drug establishment registration
and drug listing information in paper
format, unless a waiver is granted.
FDA encourages manufacturers,
repackers, and relabelers to establish a
gateway account as soon as possible so
that they will be prepared to
electronically submit drug
establishment registration and drug
listing information by June 1, 2009.
This guidance is being issued
consistent with FDA’s good guidance
practices regulation (21 CFR 10.115).
The guidance represents the agency’s
current thinking on providing regulatory
submissions in electronic format for
drug establishment registration and drug
listing information. It does not create or
confer any rights for or on any person
and does not operate to bind FDA or the
public. An alternative approach may be
used if such approach satisfies the
requirements of the applicable statutes
and regulations.
II. Comments
Interested persons may submit to the
Division of Dockets Management (see
ADDRESSES) written or electronic
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
26249
comments regarding this document.
Submit a single copy of electronic
comments or two paper copies of any
mailed comments, except that
individuals may submit one paper copy.
Comments are to be identified with the
docket number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday.
III. Paperwork Reduction Act of 1995
This guidance contains information
collection provisions that are subject to
review by the Office of Management and
Budget (OMB) under the Paperwork
Reduction Act of 1995 (44 U.S.C. 3501–
3520). The collection(s) of information
in this guidance was approved under
OMB control number 0910–0045.
IV. Electronic Access
Persons with access to the Internet
may obtain the document at https://
www.fda.gov/cder/guidance/index.htm,
https://www.fda.gov/cber/
guidelines.htm, https://www.fda.gov/
cvm/guidance/guidance.html, and
https://www.regulations.gov.
Dated: May 27, 2009.
Jeffrey Shuren,
Associate Commissioner for Policy and
Planning.
[FR Doc. E9–12743 Filed 5–28–09; 4:15 pm]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2009–N–0664]
Advisory Committee for
Pharmaceutical Science and Clinical
Pharmacology; Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Advisory
Committee for Pharmaceutical Science
and Clinical Pharmacology.
General Function of the Committee:
To provide advice and
recommendations to the agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held August 4, 2009, from 8 a.m. to 5
p.m.
Location: Hilton Washington DC/
Silver Spring, The Ballrooms, 8727
E:\FR\FM\01JNN1.SGM
01JNN1
26250
Federal Register / Vol. 74, No. 103 / Monday, June 1, 2009 / Notices
Colesville Rd., Silver Spring, MD. The
hotel telephone number is 301–589–
5200.
Contact Person: Janie Kim, Center for
Drug Evaluation and Research (HFD–
21), Food and Drug Administration,
5600 Fishers Lane (for express delivery,
5630 Fishers Lane, rm. 1093) Rockville,
MD 20857, 301–827–7001, FAX: 301–
827–6776, email:
Janie.kim@fda.hhs.gov, or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572) in the
Washington, DC area), code
3014512539. Please call the Information
Line for up-to-date information on this
meeting. A notice in the Federal
Register about last minute modifications
that impact a previously announced
advisory committee meeting cannot
always be published quickly enough to
provide timely notice. Therefore, you
should always check the agency’s Web
site and call the appropriate advisory
committee hot line/phone line to learn
about possible modifications before
coming to the meeting.
Agenda: The committee will discuss
bioequivalence recommendations for
oral vancomycin hydrochloride capsule
drug products.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/ohrms/
dockets/ac/acmenu.htm, click on the
year 2009 and scroll down to the
appropriate advisory committee link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before July 21, 2009. Oral
presentations from the public will be
scheduled between approximately 1
p.m. and 2 p.m. Those desiring to make
formal oral presentations should notify
the contact person and submit a brief
statement of the general nature of the
evidence or arguments they wish to
present, the names and addresses of
proposed participants, and an
indication of the approximate time
requested to make their presentation on
or before July 13, 2009. Time allotted for
each presentation may be limited. If the
number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
VerDate Nov<24>2008
15:29 May 29, 2009
Jkt 217001
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by July 14, 2009.
Persons attending FDA’s advisory
committee meetings are advised that the
agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Janie Kim at
least 7 days in advance of the meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/oc/advisory/
default.htm for procedures on public
conduct during advisory committee
meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: May 20, 2009.
Randall W. Lutter,
Deputy Commissioner for Policy.
[FR Doc. E9–12627 Filed 5–29–09; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2009–N–0664]
Dermatologic and Ophthalmic Drugs
Advisory Committee; Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Dermatologic
and Ophthalmic Drugs Advisory
Committee.
General Function of the Committee:
To provide advice and
recommendations to the agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on June 26, 2009, from 8 a.m. to 5
p.m.
Location: Hilton Washington DC/
Silver Spring, Maryland Ballrooms,
8727 Colesville Rd., Silver Spring, MD.
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
The hotel phone number is 301–589–
5200.
Contact Person: Paul Tran, Center for
Drug Evaluation and Research (HFD–
21), Food and Drug Administration,
5600 Fishers Lane (for express delivery,
5630 Fishers Lane, Rm. 1093) Rockville,
MD 20857, 301–827–7001, FAX: 301–
827–6778, e-mail:
paul.tran@fda.hhs.gov, or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area), code
3014512534. Please call the Information
Line for up-to-date information on this
meeting. A notice in the Federal
Register about last minute modifications
that impact a previously announced
advisory committee meeting cannot
always be published quickly enough to
provide timely notice. Therefore, you
should always check the agency’s Web
site and call the appropriate advisory
committee hot line/phone line to learn
about possible modifications before
coming to the meeting.
Agenda: The committee will discuss
new drug applications (NDAs) 22–288,
BEPREVE (bepotastine besilate)
ophthalmic solution, 1.5%, ISTA
Pharmaceuticals, Inc., proposed for the
treatment of ocular itching associated
with allergic conjunctivitis, and NDA
22–358, sodium hyaluronate ophthalmic
solution, 0.18%, River Plate
Biotechnology, Inc., proposed for the
treatment of the signs and symptoms of
dry eye disease.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/ohrms/
dockets/ac/acmenu.htm, click on the
year 2009 and scroll down to the
appropriate advisory committee link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before June 17, 2009. Oral
presentations from the public will be
scheduled between approximately 9:30
a.m. to 10 a.m., and 1:30 p.m. to 2 p.m.
Those desiring to make formal oral
presentations should notify the contact
person and submit a brief statement of
the general nature of the evidence or
arguments they wish to present, the
names and addresses of proposed
E:\FR\FM\01JNN1.SGM
01JNN1
Agencies
[Federal Register Volume 74, Number 103 (Monday, June 1, 2009)]
[Notices]
[Pages 26249-26250]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-12627]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2009-N-0664]
Advisory Committee for Pharmaceutical Science and Clinical
Pharmacology; Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). The meeting will
be open to the public.
Name of Committee: Advisory Committee for Pharmaceutical Science
and Clinical Pharmacology.
General Function of the Committee: To provide advice and
recommendations to the agency on FDA's regulatory issues.
Date and Time: The meeting will be held August 4, 2009, from 8 a.m.
to 5 p.m.
Location: Hilton Washington DC/Silver Spring, The Ballrooms, 8727
[[Page 26250]]
Colesville Rd., Silver Spring, MD. The hotel telephone number is 301-
589-5200.
Contact Person: Janie Kim, Center for Drug Evaluation and Research
(HFD-21), Food and Drug Administration, 5600 Fishers Lane (for express
delivery, 5630 Fishers Lane, rm. 1093) Rockville, MD 20857, 301-827-
7001, FAX: 301-827-6776, email: Janie.kim@fda.hhs.gov, or FDA Advisory
Committee Information Line, 1-800-741-8138 (301-443-0572) in the
Washington, DC area), code 3014512539. Please call the Information Line
for up-to-date information on this meeting. A notice in the Federal
Register about last minute modifications that impact a previously
announced advisory committee meeting cannot always be published quickly
enough to provide timely notice. Therefore, you should always check the
agency's Web site and call the appropriate advisory committee hot line/
phone line to learn about possible modifications before coming to the
meeting.
Agenda: The committee will discuss bioequivalence recommendations
for oral vancomycin hydrochloride capsule drug products.
FDA intends to make background material available to the public no
later than 2 business days before the meeting. If FDA is unable to post
the background material on its Web site prior to the meeting, the
background material will be made publicly available at the location of
the advisory committee meeting, and the background material will be
posted on FDA's Web site after the meeting. Background material is
available at https://www.fda.gov/ohrms/dockets/ac/acmenu.htm, click on
the year 2009 and scroll down to the appropriate advisory committee
link.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person on or before July
21, 2009. Oral presentations from the public will be scheduled between
approximately 1 p.m. and 2 p.m. Those desiring to make formal oral
presentations should notify the contact person and submit a brief
statement of the general nature of the evidence or arguments they wish
to present, the names and addresses of proposed participants, and an
indication of the approximate time requested to make their presentation
on or before July 13, 2009. Time allotted for each presentation may be
limited. If the number of registrants requesting to speak is greater
than can be reasonably accommodated during the scheduled open public
hearing session, FDA may conduct a lottery to determine the speakers
for the scheduled open public hearing session. The contact person will
notify interested persons regarding their request to speak by July 14,
2009.
Persons attending FDA's advisory committee meetings are advised
that the agency is not responsible for providing access to electrical
outlets.
FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
physical disabilities or special needs. If you require special
accommodations due to a disability, please contact Janie Kim at least 7
days in advance of the meeting.
FDA is committed to the orderly conduct of its advisory committee
meetings. Please visit our Web site at https://www.fda.gov/oc/advisory/default.htm for procedures on public conduct during advisory committee
meetings.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: May 20, 2009.
Randall W. Lutter,
Deputy Commissioner for Policy.
[FR Doc. E9-12627 Filed 5-29-09; 8:45 am]
BILLING CODE 4160-01-S